Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACTINIUM PHARMACEUTICALS, INC.

(ATNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Number of employees : 32 people.
Managers
Name Title Age Since
Sandesh Seth Chairman & Chief Executive Officer 56 2017
Steve O'Loughlin Chief Financial Officer 36 2017
Mark S. Berger, Dr. Chief Medical Officer 66 2017
Dale L. Ludwig, Dr. Chief Scientific & Technology Officer 59 2018
Avinash Desai, Dr. Executive VP-Clinical Development & Operations - 2020
Mary Mei Chen, Dr. Vice President-Clinical Development - 2020
C. David Nicholson, Dr. Lead Independent Director 65 2017
Richard I. Steinhart Independent Director 63 2013
Ajit S. Shetty, Dr. Independent Director 73 2017
Jeffrey W. Chell, Dr. Independent Director 66 2018
Members of the board
Name Title Age Since
Sandesh Seth Chairman & Chief Executive Officer 56 2017
C. David Nicholson, Dr. Lead Independent Director 65 2017
Richard I. Steinhart Independent Director 63 2013
Ajit S. Shetty, Dr. Independent Director 73 2017
Jeffrey W. Chell, Dr. Independent Director 66 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 21,331,314 21,021,309 98.5% 0 0.0% 98.5%
Shareholders
NameEquities%
The Vanguard Group, Inc. 808,015 4.00%
District 2 Capital LP 357,467 1.77%
Rubric Capital Management LP 294,683 1.46%
Michael Bigger 292,729 1.45%
Armistice Capital LLC 203,331 1.01%
Sio Capital Management LLC 189,062 0.94%
J. Goldman & Co. LP 168,749 0.84%
BlackRock Fund Advisors 162,299 0.80%
Geode Capital Management LLC 152,678 0.76%
Anson Funds Management LP 137,128 0.68%
Company contact information
Actinium Pharmaceuticals, Inc.
275 Madison Avenue
7th floor
New York, NY 10016

Phone : +1.646.677.3870
Web : http://www.actiniumpharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Actinium Pharmaceuticals, Inc.